In Vivo Dosimetry for Single-Fraction Targeted Intraoperative Radiotherapy (TARGIT) for Breast Cancer

Eaton, D.; Best, B. G.; Brew‐Graves, Chris; Duck, Stephen C.; Ghaus, Tabasom; Gonzalez, Regina; Pigott, K.; Reynolds, Claire; Williams, Norman; Keshtgar, Mohammed

doi:10.1016/j.ijrobp.2011.11.012

Cited by 25 publications

(39 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our experimental measurements indicate that the dosimetric uncertainty could be up to 10% for IB‐IORT source with spherical applicators, which is also consistent with the reported literature 27, 28. The major uncertainty sources of this study are: cancer cell distribution calculation at different depth (~3%), shell volume calculations at different depth (~3%), and the dose (~10%).…”

Section: Discussionsupporting

confidence: 89%

Therapeutic analysis of Intrabeam‐based intraoperative radiation therapy in the treatment of unicentric breast cancer lesions utilizing a spherical target volume model

Schwid

Donnelly

Zhang

2017

J Applied Clin Med Phys

View full text Add to dashboard Cite

It is postulated that the outcomes in treating breast cancer with intraoperative radiotherapy (IORT) would be affected by the residual cancer cell distribution within the tumor bed. The three‐dimensional (3D) radiation doses of IntrabeamTM (IB) IORT with a 4‐cm spherical applicator at the energy of 50 and 40 kV were calculated. The modified linear quadratic model (MLQ) was used to estimate the radiobiological responses of the cancer cells and interspersed normal tissues with various radiosensitivities. By comparing the average survival fraction of normal tissues in IB‐IORT and uniform dose treatment for the same level of cancer cell killing, the therapeutic ratios (TRs) were derived. The equivalent uniform dose (EUD) was found to increase with the prescription dose and decrease with the cancer cell infiltrating distance. For 50 kV beam at the 20 Gy prescription dose, the EUDs are 18.03, 16.49 and 13.56, 11. 29, and 9.28 Gy respectively, for 1.5, 3.0, 6.0, 9, and 15.0 mm of the cancer cell infiltrating distance into surrounding tissue. The dose rate of 50 kV is at least 1.87× higher than that of 40 kV beam. The EUDs of 50 kV beam are up to 15% higher than that of the 40 kV beam. The TR increases with the prescription dose, but decreases with the distance of cancer cell infiltration distance. Average TRs of 50 kV beam are up to 30% larger than that of 40 kV beam. In conclusion, IB‐IORT can provide a possible therapeutic advantage on sparing more normal tissue compared with the External Beam IORT (EB‐IORT) for shallowly populated unicentric breast lesion. Our data suggest that IB‐IORT dose size should be adjusted based on the individual patient's cancer cell infiltrating distance for delivering an effective dose, one dose‐fits‐all regimen may have undertreated some patients with large cancer infiltrating distance.

show abstract

Section: Discussionsupporting

confidence: 89%

Therapeutic analysis of Intrabeam‐based intraoperative radiation therapy in the treatment of unicentric breast cancer lesions utilizing a spherical target volume model

Schwid

Donnelly

Zhang

2017

J Applied Clin Med Phys

View full text Add to dashboard Cite

show abstract

“…The patient skin recorded doses ranging from 0.2 Gy to 1.5 Gy are below the threshold for severe skin toxicity ( 6 Gy) and reflect the different tissue thicknesses overlying the applicator. our single patient dose values are within the range of those recorded by Fogg et al with a reported maximum average dose of 2.93  1.46 Gy and Eaton et al [18] with a mean measured skin dose of 2.9  1.6 Gy.…”

supporting

confidence: 86%

“…The calibration of TLDs (LiF: Mg, 3  3 1 mm 3 , TLD700) was done using the proposed methodology by Eaton et al and the suggestions of kron et al [17,18]. Typically, four TLDs were used per packet in order to exclude outliers and reduce the standard deviation of measurements.…”

Section: Clinical Studymentioning

confidence: 99%

Monte-Carlo dosimetry for intraoperative radiotherapy using a low energy x-ray source

et al. 2015

View full text Add to dashboard Cite

“…Various dosimeters have been investigated for use as in vivo dosimeters with TARGIT including radiochromic film and thermoluminescence dosimeters (TLDs). 4,5 Potential candidates for in vivo dosimetry of TARGIT procedures are optically stimulated luminescence dosimeters (OSLDs) and RTQA2 radiochromic film. To the best of our knowledge these dosimeters have not been used for in vivo dosimetry with TARGIT.…”

Section: Introductionmentioning

confidence: 99%

In vivo dosimetry with optically stimulated dosimeters and RTQA2 radiochromic film for intraoperative radiotherapy of the breast

et al. 2013

View full text Add to dashboard Cite

show abstract

In Vivo Dosimetry for Single-Fraction Targeted Intraoperative Radiotherapy (TARGIT) for Breast Cancer

Cited by 25 publications

References 17 publications

Therapeutic analysis of Intrabeam‐based intraoperative radiation therapy in the treatment of unicentric breast cancer lesions utilizing a spherical target volume model

Therapeutic analysis of Intrabeam‐based intraoperative radiation therapy in the treatment of unicentric breast cancer lesions utilizing a spherical target volume model

Monte-Carlo dosimetry for intraoperative radiotherapy using a low energy x-ray source

In vivo dosimetry with optically stimulated dosimeters and RTQA2 radiochromic film for intraoperative radiotherapy of the breast

Contact Info

Product

Resources

About